INTRANASAL TREATMENT OF PERENNIAL ALLERGIC RHINITIS - COMPARISON OF AZELASTINE NASAL SPRAY AND BUDESONIDE NASAL AEROSOL

被引:0
作者
GASTPAR, H
AURICH, R
PETZOLD, U
DOROW, P
ENZMANN, H
GERING, R
KOCHY, HP
PHILIPP, A
RENZ, W
WENDENBURG, G
机构
[1] UNIV MUNICH,EAR NOSE & THROAT CLIN,W-8000 MUNICH 2,GERMANY
[2] ASTA MED AG,MED RES DEPT,FRANKFURT,GERMANY
[3] DRK HOSP MARK BRANDENBURG,BERLIN,GERMANY
[4] UNIV HEIDELBERG,ENT CLIN,W-6900 HEIDELBERG,GERMANY
[5] HOSP GERMAN ARMED FORCES,DETMOLD,GERMANY
[6] HANNOVER MED SCH,ENT CLIN,HANNOVER,GERMANY
来源
ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH | 1993年 / 43-1卷 / 04期
关键词
ALLERGODIL(R); ANTIALLERGIC DRUGS; AZELASTINE; CLINICAL STUDIES; BUDESONIDE; CAS; 58581-89-8; 51333-22-3; RADETHAZIN(R); RHINITIS; PERENNIAL ALLERGIC; RHINOLAST(R);
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The efficacy and tolerability of azelastine (CAS 58581-89-8) nasal spray (0.14 mg/nostril b.i.d.) and budesonide (CAS 51333-22-3) nasal aerosol (0.05 mg/nostril b.i.d.) were compared in a 6-week, multicentre, parallel group study of 193 patients suffering from perennial allergic rhinitis. Total rhinitis symptom complex (TSC) scores derived from 10 rhinitis symptoms improved during treatment by a mean of 11.4 +/- 6.8 with azelastine and 10.8 +/- 6.4 with budesonide. Response rates, defined as a decrease in TSC of at least 50 % at the end of therapy, was 79 % with azelastine and 73 % with budesonide. There were no significant differences between the treatment groups with respect to either target variable. Objective measurements of nasal flow rate showed a return to normal values during the 6-week therapy. Signs of rhinitis identified by rhinoscopic examination improved in parallel to symptoms. Both medications were well tolerated. The incidence of adverse events of possibly causal relationship to therapy was low. The most frequent event in azelastine treated patients was the experience of an ''unpleasant'' taste or smell. Occasional epistaxis occurred in both treatment groups but more frequently with budesonide. Results indicate that with the dose used azelastine nasal spray is an effective treatment for perennial allergic rhinitis comparable to that of budesonide nasal aerosol.
引用
收藏
页码:475 / 479
页数:5
相关论文
共 50 条
[31]   A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis [J].
Carr, Warner ;
Bernstein, Jonathan ;
Lieberman, Phil ;
Meltzer, Eli ;
Bachert, Claus ;
Price, David ;
Munzel, Ullrich ;
Bousquet, Jean .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (05) :1282-U155
[32]   Combination treatment of allergic rhinitis using ketotifen fumarate and budesonide administered as nasal sprays [J].
Wang, Shu-Zhen ;
Yao, Yuan ;
Zhang, Xiu-Ju ;
Duan, Xing ;
Guo, Liang-Rong ;
Jia, Yun ;
Wang, Dan ;
Tian, Yong-Sheng .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (04) :195-197
[33]   Comparison of once daily fluticasone propionate aqueous nasal spray with once daily budesonide reservoir powder device in patients with perennial rhinitis [J].
Kivisaari, E ;
Baker, RC ;
Price, MJ .
CLINICAL AND EXPERIMENTAL ALLERGY, 2001, 31 (06) :855-863
[34]   A Multicenter Randomized Double-Blind 2-Week Comparison Study of Azelastine Nasal Spray 0.1% versus Levocabastine Nasal Spray 0.05% in Patients with Moderate-to-Severe Allergic Rhinitis [J].
Han, Demin ;
Chen, Lei ;
Cheng, Lei ;
Liu, Shixi ;
Fu, Zheng ;
Zhang, Wei ;
Wang, Chengshuo ;
Xi, Lin ;
Zhang, Luo .
ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES, 2011, 73 (05) :260-265
[35]   Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis [J].
Baena-Cagnani, Carlos E. ;
Patel, Piyush .
CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (09) :2047-2055
[36]   Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis [J].
LaForce, Craig F. ;
Carr, Warner ;
Tilles, Stephen A. ;
Chipps, Bradley E. ;
Storms, William ;
Meltzer, Eli O. ;
Edwards, Michael .
ALLERGY AND ASTHMA PROCEEDINGS, 2010, 31 (02) :132-140
[37]   Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitis [J].
Berger, William E. .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (01) :91-102
[38]   A COMPARISON OF THE EFFICACY AND PATIENT ACCEPTABILITY OF BUDESONIDE AND BECLOMETHASONE DIPROPIONATE AQUEOUS NASAL SPRAYS IN PATIENTS WITH PERENNIAL RHINITIS [J].
ADAMOPOULOS, G ;
MANOLOPOULOS, L ;
GIOTAKIS, I .
CLINICAL OTOLARYNGOLOGY, 1995, 20 (04) :340-344
[39]   Double-blind, placebo-controlled trial of reformulated azelastine nasal spray in patients with seasonal allergic rhinitis [J].
Bernstein, Jonathan A. ;
Prenner, Bruce ;
Ferguson, Berrylin J. ;
Portnoy, Jay ;
Wheeler, William J. ;
Sacks, Harry J. .
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2009, 23 (05) :512-517
[40]   A Clinical Study to Assess the Efficacy and Safety of MP-AzeFlu Nasal Spray in Comparison to Commercially Available Azelastine Hydrochloride and Fluticasone Propionate Nasal Sprays in Chinese Volunteers with Allergic Rhinitis [J].
Bing Zhou ;
Lei Cheng ;
Jing Pan ;
Huizhong Wang ;
Yongde Jin ;
Changqing Zhao ;
Peng Lin ;
Guolin Tan ;
Hongyan Fang ;
Hua Zhang ;
Huifang Zhou ;
Yaowu Dong ;
Hans Christian Kuhl ;
Rajesh Kumar Ramalingam ;
Duc Tung Nguyen .
Pulmonary Therapy, 2023, 9 :411-427